Indomethacin Capsules 25mg for Pain Relief and Inflammation

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Still deciding? Get samples of US$ 0/Piece
Request Sample
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Years of Export Experience
The export experience of the supplier is more than 10 years
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Importers and Exporters
The supplier has import and export rights
Management Certification
The supplier has quality management system certification, including:
ISO9001:2015 certificate
ISO45001:2018 certificate
ISO14001
to see all verified strength labels (20)
  • Indomethacin Capsules 25mg for Pain Relief and Inflammation
  • Indomethacin Capsules 25mg for Pain Relief and Inflammation
  • Indomethacin Capsules 25mg for Pain Relief and Inflammation
  • Indomethacin Capsules 25mg for Pain Relief and Inflammation
  • Indomethacin Capsules 25mg for Pain Relief and Inflammation
  • Indomethacin Capsules 25mg for Pain Relief and Inflammation
Find Similar Products

Basic Info.

Model NO.
AMC11007-01
Suitable for
Elderly, Children, Adult
State
Solid
Shape
Capsules
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Packing
10*10/Box, 200boxes/CTN
CTN Size
53*30.5*27.5cm
OEM/ODM
OEM/ODM
Transport
Shipping
Transport Package
10′s*10/Box
Specification
25mg
Trademark
Medipharm or OEM
Origin
China
HS Code
3004909099
Production Capacity
500000boxes/CTN

Product Description

Contra-indications: 
Active peptic ulcer or a history of recurrent gastro-intestinal lesions. Sensitivity to aspirin, indometacin or other non-steroidal anti-inflammatory agents. 
Pregnancy or lactation. 
Patients operating machinery. 
Patients with epilepsy, parkinsonism, psychiatric disturbances or porphyria. 
Children, since conditions for safe use have not been established. 
Severe heart failure.

Adverse Effects:
Most adverse effects are dose related 
Gastro-intestinal adverse effects are common and include anorexia, nausea (with or without vomiting) dyspepsia, abdominal pain and diarrhoea. Infrequently, ulceration of the upper GI tract, sometimes with perforation and haemorrhage, has occurred. Acute pancreatitis has been reported. Hepatic involvement is rare, though fatal cases of hepatitis and jaundice have been reported. 
CNS effects are also common. Severe frontal headache may occur in 25 - 50% of patients who take the drug chronically. Dizziness, light-headedness, vertigo and mental confusion are also frequent. Depression and psychosis have also been reported but the incidence is less than 1%. 
Haemopoietic reactions, including neutropenia, thrombocytopenia and, rarely, aplastic anaemia have been reported. 
Hypersensitivity reactions, manifested as rashes, itching, urticaria or rarely acute asthma, may occur. 
Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.

Drug Interactions:
1. The plasma concentration of Indometacin is increased. 
2. Frusemide. The natriuretic and anti-hypersensitivity effects are antagonised by Indometacin. 
3. Thiazide diuretics and beta-blocking agents. Indometacin reduces the anti-hypertensive effects of these compounds. 
4. Antacids. The bioavailability of Indometacin may be reduced by concomitant antacid therapy. 
5. Acute renal failure has been reported with concomitant Indometacin therapy.

Precautions & Warning:
Indometacin should be used with great care in elderly patients. Indometacin should be used with caution in patients with impaired renal function. Indometacin inhibits platelet aggregation and prolongs bleeding time. It should be used with caution therefore in patients with bleeding disorders, and concurrent administration of anti-coagulant agent may be hazardous because of increased risk of gastrointestinal bleeding
Peptic ulcer has been reported in a small proportion of patients. If G.I. bleeding occurs, indometacin should be discontinued immediately. Indometacin may mask the signs and symptoms of infection. If clinical signs of hepatic disease develop, or if liver function tests become abnormal, indometacin should be withdrawn. Indometacin should be given with or immediately after food in order to lessen the incidence and severity of gastrointestinal side-effects. 
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms.

Treatment/antidote in The Event of Overdose:
Gastric lavage should be performed if ingestion is recent. Otherwise, supportive measures and observation.

Storage instructions:
Store below 25ºC. Protect from moisture. Keep out of reach of children.

 
Model NO AMC11007-01
OEM/ODM Support
Specification 25mg
Origin China
Production Capacity 500000boxes/Month
Pharmaceutical Technology Chemical Synthesis
Transport Package 10X10′s/Box or OEM
Trademark Medipharm or OEM

--------------------------------------------------------------------------------------------------
 
Indomethacin Capsules 25mg for Pain Relief and Inflammation
 
Indomethacin Capsules 25mg for Pain Relief and Inflammation
 
 
 
 
Indomethacin Capsules 25mg for Pain Relief and Inflammation
 
 
Indomethacin Capsules 25mg for Pain Relief and Inflammation
 
Indomethacin Capsules 25mg for Pain Relief and Inflammation

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier